Study to Evaluate the Safety & Performance of the Xpert(TM) Stent in Treating Below-the-knee Lesions in Patients Undergoing Percutaneous Intervention for Chronic CLI.

Peripheral Vascular Diseases Clinical Trial

— XCELL  

Official title:

Phase 1 Study of Xpert(TM) Nitinol Stenting for Critically Ischemic Lower Limbs

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00515346
• Other study ID #: G060029
• Status: Completed
• Phase: Phase 1
• First received: August 9, 2007
• Last updated: December 16, 2013
• Start date: July 2006
• Est. completion date: September 2011

Study information

• Verified date: December 2013
• Source: VIVA Physicians
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and performance of the Xpert(TM) self-expanding stent in infrapopliteal lesions as part of an overall treatment strategy in patients undergoing percutaneous intervention for the treatment of documented chronic critical limb ischemia (CLI).

Description:

Peripheral arterial disease (PAD) of the lower extremities affects roughly 25 million Americans annually. The diabetic population is particularly prone to the most severe clinical problems associated with PAD and the amputation rate amongst such patients is elevated five-fold. It has been shown that patients who undergo amputation for PAD/CLI have a much higher mortality rate in the months that follow.

Despite medical advances in the fields of pharmacology and wound care, the vast majority of patients who present with CLI will ultimately require amputation in the absence of improved blood flow. Recently, much attention has been directed towards less invasive endovascular solutions for treating patients with CLI. This study will evaluate approximately 140 subjects with Rutherford Class IV-VI PAD in a multi-center study in order to accurately estimate limb salvage rates for this treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: September 2011
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria:

• Patient has documented wound care greater than or equal to 2 weeks prior to enrollment

• Subject understands the duration of the study and its follow up visit requirements

• Female subjects of childbearing potential have a negative pregnancy test less than 7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation

• Subject has documented chronic critical limb ischemia in the target limb for two weeks with Rutherford Category 4, 5 or 6

• Subject must have one of 5 approved non-invasive test results of the target limb within two weeks of enrollment.

Exclusion Criteria:

• Life expectancy of less than 12 months

• Cerebrovascular accident (CVA) or myocardial infarction (MI) within 3 months prior to enrollment

• Inability to walk (with assistance is accepted)

• Previous bypass surgery to target limb less than 30 days prior to study procedure

• Acute thrombus at the lesion site(s)

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Critical Limb Ischemia
• Peripheral Arterial Disease
• Peripheral Vascular Diseases
• Vascular Diseases

Intervention

Device:
• Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia

Locations

Country	Name	City	State
United States	VIVA Physicians Inc.	San Jose	California

Sponsors (2)

Lead Sponsor	Collaborator
VIVA Physicians	Prairie Education and Research Cooperative

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Amputation free survival at 12 months in the target limb. Amputation for the primary endpoint is defined as a major, unplanned, amputation of the target limb through the 12 month visit where prosthesis is required for standing or walking.		1 year	No
Secondary	Assess improvement in wound healing; assess restenosis; measure target lesion revascularization to maintain patency at 12 months; measure ankle/brachial improvement level; assess stent integrity; characterize improvement in health related quality of life		2 years	No